The rise of copyright’s blockbuster initially drove a surge for pharma, however recent shifts present a uncertain picture for shareholders. Lower-cost alternatives are reducing profits, and ongoing patent challenges https://agnesnrns344877.therainblog.com/39722274/sildenafil-and-big-pharma-a-precarious-play